E. Cioli , L. Boscolo Bielo , S. Napolitano , E. Martinelli , T. Troiani , T.P. Latiano , R. Bordonaro , S. Pisconti , C. Lotesoriere , E. Tamburini , A. Avallone , S. Lonardi , D. Iacono , P.S. Tagliaferri , C. Damonte , C. Cremolini , N. Fazio , F. Ciardiello , G. Martini , D. Ciardiello
{"title":"整合组织(TBx)和液体活检(LBx)综合基因组图谱预测抗egfr治疗在转移性结直肠癌(mCRC)中的疗效:来自CAPRI-2 GOIM研究的发现","authors":"E. Cioli , L. Boscolo Bielo , S. Napolitano , E. Martinelli , T. Troiani , T.P. Latiano , R. Bordonaro , S. Pisconti , C. Lotesoriere , E. Tamburini , A. Avallone , S. Lonardi , D. Iacono , P.S. Tagliaferri , C. Damonte , C. Cremolini , N. Fazio , F. Ciardiello , G. Martini , D. Ciardiello","doi":"10.1016/j.annonc.2025.05.025","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Page S10"},"PeriodicalIF":65.4000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"13P Integrating tissue (TBx) and liquid biopsy (LBx) comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer (mCRC): Findings from the CAPRI-2 GOIM study\",\"authors\":\"E. Cioli , L. Boscolo Bielo , S. Napolitano , E. Martinelli , T. Troiani , T.P. Latiano , R. Bordonaro , S. Pisconti , C. Lotesoriere , E. Tamburini , A. Avallone , S. Lonardi , D. Iacono , P.S. Tagliaferri , C. Damonte , C. Cremolini , N. Fazio , F. Ciardiello , G. Martini , D. Ciardiello\",\"doi\":\"10.1016/j.annonc.2025.05.025\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":8000,\"journal\":{\"name\":\"Annals of Oncology\",\"volume\":\"36 \",\"pages\":\"Page S10\"},\"PeriodicalIF\":65.4000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0923753425002285\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0923753425002285","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
13P Integrating tissue (TBx) and liquid biopsy (LBx) comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer (mCRC): Findings from the CAPRI-2 GOIM study
期刊介绍:
Annals of Oncology, the official journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, offers rapid and efficient peer-reviewed publications on innovative cancer treatments and translational research in oncology and precision medicine.
The journal primarily focuses on areas such as systemic anticancer therapy, with a specific emphasis on molecular targeted agents and new immune therapies. We also welcome randomized trials, including negative results, as well as top-level guidelines. Additionally, we encourage submissions in emerging fields that are crucial to personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Manuscripts related to radiotherapy, surgery, and pediatrics will be considered if they demonstrate a clear interaction with any of the aforementioned fields or if they present groundbreaking findings.
Our international editorial board comprises renowned experts who are leaders in their respective fields. Through Annals of Oncology, we strive to provide the most effective communication on the dynamic and ever-evolving global oncology landscape.